Study wrapper · #908
Comparative Cardiovascular Outcomes of Tirzepatide and Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease.
Wu JY, Lee KW, Kao CL, et al. Journal of the American Heart Association. 2026.
DOI: 10.1161/jaha.125.047018PubMed: 42466510
Editor's note
This propensity-matched cohort is directly relevant to tirzepatide's cardiometabolic profile and reports consistent benefits across several outcomes. The signal is encouraging but observational, and the authors themselves call for prospective validation. Residual confounding and the one-year window are meaningful limits.
Plain-language abstract
In a matched real-world study of over 16,000 patients with type 2 diabetes and established cardiovascular disease, tirzepatide was associated with a lower one-year risk of major cardiovascular events and death than other GLP-1 receptor agonists.
Related coverage
Weak / none
Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial.
Journal of medical economicsn=——2026
Mixed
Sleeve gastrectomy versus tirzepatide to improve survival among patients with stage 5 CKD: A Markov decision analysis.
American journal of surgeryn=——2026
Mixed
Development and validation of a multiplexed LC-HRMS method for nine GLP-1 receptor agonists and its pharmaceutical application.
Journal of chromatography. An=——2026